Foster & Motley’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Foster & Motley's VRTX Position: Q2 2026 in Review
Foster & Motley opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 414 shares worth $206K. The stake represents 0.01% of the portfolio and ranks #401 among its holdings. This is a return to the name: Foster & Motley previously reported a position in VRTX as recently as Q2 2025.
Foster & Motley first reported a position in VRTX in Q2 2023 and has held it in 6 quarters since. The position peaked at $219K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Foster & Motley held 414 shares of Vertex Pharmaceuticals worth $206K as of Q2 2026.
- Vertex Pharmaceuticals was a new Foster & Motley position in Q2 2026.
- Vertex Pharmaceuticals made up 0.01% of Foster & Motley's portfolio in Q2 2026, its #401 holding.
- Foster & Motley first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
- Foster & Motley's Vertex Pharmaceuticals position peaked at $219K in Q1 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Foster & Motley's 13F filing for Q2 2026, filed 7 Aug 2026.